Cutaneous reactions after SARS-CoV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases

被引：169

作者：

Catala, A. ^{[1
]}

Munoz-Santos, C. ^{[2
]}

Galvan-Casas, C. ^{[3
]}

Roncero Riesco, M. ^{[4
]}

Revilla Nebreda, D. ^{[4
]}

Sola-Truyols, A. ^{[5
]}

Giavedoni, P. ^{[1
]}

Llamas-Velasco, M. ^{[6
]}

Gonzalez-Cruz, C. ^{[7
]}

Cubiro, X. ^{[8
]}

Ruiz-Villaverde, R. ^{[9
]}

Gomez-Armayones, S. ^{[1
]}

Gil Mateo, M. P. ^{[10
]}

Pesque, D. ^{[11
]}

Marcantonio, O. ^{[11
]}

Fernandez-Nieto, D. ^{[12
]}

Romani, J. ^{[13
]}

Iglesias Pena, N. ^{[14
]}

Carnero Gonzalez, L. ^{[15
]}

Tercedor-Sanchez, J. ^{[16
]}

Carretero, G. ^{[17
]}

Masat-Tico, T. ^{[18
]}

Rodriguez-Jimenez, P. ^{[6
]}

Gimenez-Arnau, A. M. ^{[11
]}

Utrera-Busquets, M. ^{[19
]}

Vargas Laguna, E. ^{[20
]}

Angulo Menendez, A. G. ^{[21
]}

San Juan Lasser, E.

Iglesias-Sancho, M. ^{[22
]}

Alonso Naranjo, L. ^{[23
]}

Hiltun, I ^{[24
]}

Cutillas Marco, E. ^{[25
]}

Polimon Olabarrieta, I ^{[3
]}

Marinero Escobedo, S. ^{[3
]}

Garcia-Navarro, X. ^{[26
]}

Calderon Gutierrez, M. J.

Baeza-Hernandez, G. ^{[27
]}

Bou Camps, L.

Toledo-Pastrana, T. ^{[28
]}

Guilabert, A. ^{[2
]}

机构：

[1] Hosp Clin Barcelona, Serv Dermatol, Barcelona, Spain

[2] Hosp Gen Granollers, Serv Dermatol, Barcelona, Spain

[3] Hosp Univ Mostoles, Serv Dermatol, Madrid, Spain

[4] Complejo Asistencial Univ Salamanca, Serv Dermatol, Salamanca, Spain

[5] Hosp Univ Son Llatzer, Serv Dermatol, Mallorca, Spain

[6] Hosp Univ La Princesa, Serv Dermatol, Madrid, Spain

[7] Hosp Univ Vall DHebron, Serv Dermatol, Barcelona, Spain

[8] Hosp Santa Creu & Sant Pau, Serv Dermatol, Barcelona, Spain

[9] Hosp Univ San Cecilio, Serv Dermatol, Granada, Spain

[10] Hosp Gen La Palma, Serv Dermatol, Santa Cruz De Tenerife, Spain

[11] Univ Autonoma Barcelona, IMIM, Hosp Mar, Serv Dermatol, Barcelona, Spain

[12] Hosp Raman & Cajal, Serv Dermatol, Madrid, Spain

[13] Parc Tauli Hosp Univ, Serv Dermatol, Barcelona, Spain

[14] Hosp Univ Lucus Augusti, Serv Dermatol, Lugo, Spain

[15] Hosp Univ Araba, Serv Dermatol, Vitoria, Spain

[16] Hosp Virgen de las Nieves, Serv Dermatol, Granada, Spain

[17] Hosp Univ Gran Canaria Doctor Negrin, Serv Dermatol, Las Palmas Gran Canaria, Spain

[18] Inst Catala Salut, CAP Cardedeu, Barcelona, Spain

[19] Hosp Comarcal Infanta Elena, Serv Dermatol, Huelva, Spain

[20] Hosp Univ Severo Ochoa, Serv Dermatol, Madrid, Spain

[21] Serv Med Penedes Vilanova & Geltru, Serv Dermatol, Barcelona, Spain

[22] Hosp Univ Sagrat Cor, Serv Dermatol, Madrid, Spain

[23] Hosp Univ Toledo, Serv Dermatol, Toledo, Spain

[24] Complejo Hosp Navarra, Serv Dermatol, Navarra, Spain

[25] Hosp Gen Univ Reina Sofia, Serv Dermatol, Murcia, Spain

[26] Consorci Sanitari Alt Penedes Garraf, Serv Dermatol, Barcelona, Spain

[27] Hosp Univ Fuenlabrada, Serv Dermatol, Madrid, Spain

[28] Hosp Quironsalud Infanta Luisa, Seville, Spain

来源：

BRITISH JOURNAL OF DERMATOLOGY | 2022年 / 186卷 / 01期

关键词：

COVID-19; VACCINATION;

D O I：

10.1111/bjd.20639

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Background Cutaneous reactions after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines are poorly characterized. Objective To describe and classify cutaneous reactions after SARS-CoV-2 vaccination. Methods A nationwide Spanish cross-sectional study was conducted. We included patients with cutaneous reactions within 21 days of any dose of the approved vaccines at the time of the study. After a face-to-face visit with a dermatologist, information on cutaneous reactions was collected via an online professional survey and clinical photographs were sent by email. Investigators searched for consensus on clinical patterns and classification. Results From 16 February to 15 May 2021, we collected 405 reactions after vaccination with the BNT162b2 (Pfizer-BioNTech; 40 center dot 2%), mRNA-1273 (Moderna; 36 center dot 3%) and AZD1222 (AstraZeneca; 23 center dot 5%) vaccines. Mean patient age was 50 center dot 7 years and 80 center dot 2% were female. Cutaneous reactions were classified as injection site ('COVID arm', 32 center dot 1%), urticaria (14 center dot 6%), morbilliform (8 center dot 9%), papulovesicular (6 center dot 4%), pityriasis rosea-like (4 center dot 9%) and purpuric (4%) reactions. Varicella zoster and herpes simplex virus reactivations accounted for 13 center dot 8% of reactions. The COVID arm was almost exclusive to women (95 center dot 4%). The most reported reactions in each vaccine group were COVID arm (mRNA-1273, Moderna, 61 center dot 9%), varicella zoster virus reactivation (BNT162b2, Pfizer-BioNTech, 17 center dot 2%) and urticaria (AZD1222, AstraZeneca, 21 center dot 1%). Most reactions to the mRNA-1273 (Moderna) vaccine were described in women (90 center dot 5%). Eighty reactions (21%) were classified as severe/very severe and 81% required treatment. Conclusions Cutaneous reactions after SARS-CoV-2 vaccination are heterogeneous. Most are mild-to-moderate and self-limiting, although severe/very severe reactions are reported. Knowledge of these reactions during mass vaccination may help healthcare professionals and reassure patients.

引用

页码：142 / 152

页数：11

共 43 条

[1] Pityriasis rosea following CoronaVac COVID-19 vaccination: a case report
Akdas, E.
Ilter, N.
Ogut, B.
Erdem, O.
[J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2021, 35 (08) : E491 - E493
[2] Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, Lindsey R.
El Sahly, Hana M.
Essink, Brandon
Kotloff, Karen
Frey, Sharon
Novak, Rick
Diemert, David
Spector, Stephen A.
Rouphael, Nadine
Creech, C. Buddy
McGettigan, John
Khetan, Shishir
Segall, Nathan
Solis, Joel
Brosz, Adam
Fierro, Carlos
Schwartz, Howard
Neuzil, Kathleen
Corey, Larry
Gilbert, Peter
Janes, Holly
Follmann, Dean
Marovich, Mary
Mascola, John
Polakowski, Laura
Ledgerwood, Julie
Graham, Barney S.
Bennett, Hamilton
Pajon, Rolando
Knightly, Conor
Leav, Brett
Deng, Weiping
Zhou, Honghong
Han, Shu
Ivarsson, Melanie
Miller, Jacqueline
Zaks, Tal
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (05) : 403 - 416
[3] Childhood bullous pemphigoid developed after the first vaccination
Baykal, C
Okan, G
Sarica, R
[J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2001, 44 (02) : 348 - 350
[4] Delayed Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2
Blumenthal, Kimberly G.
Freeman, Esther E.
Saff, Rebecca R.
Robinson, Lacey B.
Wolfson, Anna R.
Foreman, Ruth K.
Hashimoto, Dean
Banerji, Aleena
Li, Lily
Anvari, Sara
Shenoy, Erica S.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (13) : 1273 - 1277
[5] COVID-19 "second wave" and vaccines: the dermatologists' perspective
Burlando, Martina
Russo, Roberto
Cozzani, Emanuele
Parodi, Aurora
[J]. INTERNATIONAL JOURNAL OF DERMATOLOGY, 2021, 60 (07) : 889 - 890
[6] Pityriasis rosea, COVID-19 and vaccination: new keys to understand an old acquaintance
Busto-Leis, J. M.
Servera-Negre, G.
Mayor-Ibarguren, A.
Sendagorta-Cudos, E.
Feito-Rodriguez, M.
Nuno-Gonzalez, A.
Montero-Vega, M. D.
Herranz-Pinto, P.
[J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2021, 35 (08) : E489 - E491
[7] Exercise Training and Cardiac Rehabilitation in COVID-19 Patients with Cardiovascular Complications: State of Art
Calabrese, Mariaconsiglia
Garofano, Marina
Palumbo, Roberta
Di Pietro, Paola
Izzo, Carmine
Damato, Antonio
Venturini, Eleonora
Iesu, Severino
Virtuoso, Nicola
Strianese, Andrea
Ciccarelli, Michele
Galasso, Gennaro
Vecchione, Carmine
[J]. LIFE-BASEL, 2021, 11 (03):
[8] Pityriasis rosea-like eruptions following vaccination with BNT162b2 mRNA COVID-19 Vaccine
Cyrenne, B. M.
Al-Mohammedi, F.
DeKoven, J. G.
Alhusayen, R.
[J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2021, 35 (09) : E546 - E548
[9] Downs AMR, 1998, BRIT J DERMATOL, V138, P363
[10] Vaccine-induced pityriasis rosea and pityriasis rosea-like eruptions: a review of the literature
Drago, F.
Ciccarese, G.
Javor, S.
Parodi, A.
[J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 (03) : 544 - 545

← 1 2 3 4 5 →